GH240719C35000
- 0.10
- +0.06+150.00%
Guardant Health Newsroom
Top Premarket Gainers
African Agriculture (AAGR) shares surged nearly 72% in recent Friday premarket activity, shaving Thursday's 3% loss. Cosmos Health (COSM) stock was almost 59% higher after the company said Thursday it
Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36
Guardant Health (GH) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $28 to $47. Price: 30.10, Change: +1.05, Percent Change: +3.61
Express News | Guardant Health Shares up 3.1% Premarket After Guggenheim Raises to Buy From Neutral
Guggenheim Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $36
Guggenheim analyst Subbu Nambi initiates coverage on $Guardant Health(GH.US)$ with a buy rating, and sets the target price at $36.According to TipRanks data, the analyst has a success rate of 50.0% an
Express News | Guardant Health Inc : Guggenheim Raises to Buy From Neutral
American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond
USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million...
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
Even After Rising 7.4% This Past Week, Guardant Health (NASDAQ:GH) Shareholders Are Still Down 74% Over the Past Three Years
United States Liquid Biopsy Market Forecast to 2031: Company Profiles, Recent Developments and Major Deals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Liquid Biopsy Market (by Circulating Biomarker, Product, Application, Cancer Types, Non-Cancer Application, End User, Clinical Application, Sample Type), In
Guardant Health(GH.US) Director Sells US$2,787 in Common Stock
$Guardant Health(GH.US)$ Director Joyce Meghan V. sold 100 shares of common stock on Jun 4, 2024 at an average price of $27.87 for a total value of $2,787.Source: Announcement What is statement of cha
Guardant Health Shares Are Trading Higher After the Company Launched the New Guardant360 TissueNext Test. Additionally, Canaccord Genuity Maintained a Buy Rating While Raising Its Price Target to $38.
Guardant Health Shares Are Trading Higher After the Company Launched the New Guardant360 TissueNext Test. Additionally, Canaccord Genuity Maintained a Buy Rating While Raising Its Price Target to $38.
Guardant Health Is Maintained at Buy by Canaccord Genuity
Guardant Health Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $38
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health with a Buy and raises the price target from $30 to $38.
Guardant Health Introduces New Guardant360 TissueNext Test With Nearly 500 Biomarkers to Identify More Treatment Options for Patients With Advanced Cancer
Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results Upgraded test covered by
Guardant Health Initiated at Buy by Jefferies
Guardant Health Initiated at Buy by Jefferies
Guardant Health Price Target Announced at $32.00/Share by Jefferies
Guardant Health Price Target Announced at $32.00/Share by Jefferies
Express News | Guardant Health (GH.US) received its first coverage by Jefferies Financial, who gave it a buy rating and a target price of $32.00.
Jefferies Initiates Coverage On Guardant Health With Buy Rating, Announces Price Target of $32
Jefferies analyst Tycho Peterson initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $32.
Guardant Health and Washington University to Present Study at 2024 ASCO Meeting Highlighting Utility of CtDNA to Address Racial Inequities in the Use of Targeted Therapies and Enrollment in Clinical Trials
Data from study using Guardant360 blood test show Black patients with PIK3CA mutations in advanced breast cancer were less likely than White patients to be enrolled in clinical trials and receive targeted
Guardant Health Inc: Jefferies starts insurance with a buy rating; target share price is $32
Guardant Health Inc: Jefferies starts insurance with a buy rating; target share price is $32